Oxygen causes fetal pulmonary vasodilation through activation of a calcium-dependent potassium channel

Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):8089-94. doi: 10.1073/pnas.93.15.8089.

Abstract

At birth, pulmonary vasodilation occurs as air-breathing life begins. The mechanism of O2-induced pulmonary vasodilation is unknown. We proposed that O2 causes fetal pulmonary vasodilation through activation of a calcium-dependent potassium channel (KCa) via a cyclic nucleotide-dependent kinase. We tested this hypothesis in hemodynamic studies in acutely prepared fetal lambs and in patch-clamp studies on resistance fetal pulmonary artery smooth muscle cells. Fetal O2 tension (PaO2) was increased by ventilating the ewe with 100% O2, causing fetal total pulmonary resistance to decrease from 1.18 +/- 0.14 to 0.41 +/- 0.03 mmHg per ml per min. Tetraethylammonium and iberiotoxin, preferential KCa-channel inhibitors, attenuated O2-induced fetal pulmonary vasodilation, while glibenclamide, an ATP-sensitive K+-channel antagonist, had no effect. Treatment with either a guanylate cyclase antagonist (LY83583) or cyclic nucleotide-dependent kinase inhibitors (H-89 and KT 5823) significantly attenuated O2-induced fetal pulmonary vasodilation. Under hypoxic conditions (PaO2 = 25 mmHg), whole-cell K+-channel currents (Ik) were small and were inhibited by 1 mM tetraethylammonium or 100 nM charybdotoxin (CTX; a specific KCa-channel blocker). Normoxia (PaO2 = 120 mmHg) increased Ik by more than 300%, and this was reversed by 100 nM CTX. Nitric oxide also increased Ik. Resting membrane potential was -37.2 +/- 1.9 mV and cells depolarized on exposure to CTX, while hyperpolarizing in normoxia. We conclude that O2 causes fetal pulmonary vasodilation by stimulating a cyclic nucleotide-dependent kinase, resulting in KCa-channel activation, membrane hyperpolarization, and vasodilation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Alkaloids / pharmacology
  • Aminoquinolines / pharmacology
  • Animals
  • Carbazoles*
  • Charybdotoxin / pharmacology
  • Endothelium, Vascular / physiology
  • Enzyme Inhibitors / pharmacology
  • Female
  • Fetus
  • Glyburide / pharmacology
  • Guanylate Cyclase / antagonists & inhibitors
  • Hypoxia
  • Indoles*
  • Isoquinolines / pharmacology
  • Membrane Potentials / drug effects
  • Models, Cardiovascular
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / embryology
  • Muscle, Smooth, Vascular / physiology*
  • Nitric Oxide / pharmacology
  • Nitric Oxide Synthase / metabolism
  • Oxygen / pharmacology*
  • Patch-Clamp Techniques
  • Peptides / pharmacology
  • Potassium Channel Blockers
  • Potassium Channels / physiology*
  • Pregnancy
  • Protein Kinase Inhibitors
  • Pulmonary Artery / drug effects
  • Pulmonary Artery / embryology
  • Pulmonary Artery / physiology*
  • Sheep
  • Sulfonamides*
  • Tetraethylammonium
  • Tetraethylammonium Compounds / pharmacology
  • Vasodilation / drug effects
  • Vasodilation / physiology*

Substances

  • Alkaloids
  • Aminoquinolines
  • Carbazoles
  • Enzyme Inhibitors
  • Indoles
  • Isoquinolines
  • Peptides
  • Potassium Channel Blockers
  • Potassium Channels
  • Protein Kinase Inhibitors
  • Sulfonamides
  • Tetraethylammonium Compounds
  • Charybdotoxin
  • KT 5823
  • Nitric Oxide
  • Tetraethylammonium
  • iberiotoxin
  • 6-anilino-5,8-quinolinedione
  • Nitric Oxide Synthase
  • Guanylate Cyclase
  • N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide
  • Oxygen
  • Glyburide